MiMedx Group is trading 10.2% down at $3.80 in pre-market following a sharp year-over-year revenue decline and the announcement of a $350 million definitive agreement to acquire Sanara MedTech.
- The company reported an adjusted loss per share as its Wound segment faced a steep decline driven by recent Medicare reimbursement changes.
- Despite strong growth in the Surgical franchise and reaffirmed 2026 guidance, investor sentiment is weighed down by potential dilution and uncertainty surrounding the Sanara acquisition.